J. Cobaleda

824 total citations
20 papers, 615 citations indexed

About

J. Cobaleda is a scholar working on Pharmacology, Oncology and Ophthalmology. According to data from OpenAlex, J. Cobaleda has authored 20 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 6 papers in Oncology and 5 papers in Ophthalmology. Recurrent topics in J. Cobaleda's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug-Induced Ocular Toxicity (5 papers) and Cancer Treatment and Pharmacology (4 papers). J. Cobaleda is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug-Induced Ocular Toxicity (5 papers) and Cancer Treatment and Pharmacology (4 papers). J. Cobaleda collaborates with scholars based in Spain, United States and Sweden. J. Cobaleda's co-authors include Adrián LLerena, J. Benítez, Carmen Martínez, Julio Benítez, Daisy Schalling, J. Benítez, Leif Bertilsson, Gunnar Edman, Eva Peñas‐Lledó and Pedro Dorado and has published in prestigious journals such as Anesthesiology, Journal of Neurology Neurosurgery & Psychiatry and Clinical Pharmacology & Therapeutics.

In The Last Decade

J. Cobaleda

20 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Cobaleda Spain 14 376 146 111 100 84 20 615
M L Dahl Sweden 11 445 1.2× 146 1.0× 116 1.0× 89 0.9× 121 1.4× 17 624
U. Jeppesen Denmark 8 327 0.9× 149 1.0× 150 1.4× 94 0.9× 204 2.4× 10 824
Sachiyo Morita Japan 13 292 0.8× 94 0.6× 122 1.1× 88 0.9× 118 1.4× 27 471
J rgen Brockm ller Germany 11 449 1.2× 212 1.5× 57 0.5× 169 1.7× 147 1.8× 13 757
Jesús Novalbos Spain 17 217 0.6× 91 0.6× 170 1.5× 162 1.6× 125 1.5× 47 795
Karin Kramer Nielsen Denmark 16 384 1.0× 163 1.1× 130 1.2× 203 2.0× 220 2.6× 28 921
Linda S. W. Steijns Netherlands 7 307 0.8× 169 1.2× 177 1.6× 65 0.7× 68 0.8× 9 544
Angela Seeringer Germany 18 261 0.7× 154 1.1× 154 1.4× 193 1.9× 122 1.5× 30 926
Ida Rudberg Norway 9 285 0.8× 87 0.6× 198 1.8× 135 1.4× 173 2.1× 11 631
Arzu Gunes Sweden 15 265 0.7× 109 0.7× 221 2.0× 133 1.3× 168 2.0× 23 832

Countries citing papers authored by J. Cobaleda

Since Specialization
Citations

This map shows the geographic impact of J. Cobaleda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Cobaleda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Cobaleda more than expected).

Fields of papers citing papers by J. Cobaleda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Cobaleda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Cobaleda. The network helps show where J. Cobaleda may publish in the future.

Co-authorship network of co-authors of J. Cobaleda

This figure shows the co-authorship network connecting the top 25 collaborators of J. Cobaleda. A scholar is included among the top collaborators of J. Cobaleda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Cobaleda. J. Cobaleda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
LLerena, Adrián, et al.. (2020). Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative. Drug metabolism and drug interactions. 35(3). 5 indexed citations
2.
Xie, Ting, Maria G. Stathopoulou, Fernando de Andrés, et al.. (2017). VEGF-related polymorphisms identified by GWAS and risk for major depression. Translational Psychiatry. 7(3). e1055–e1055. 33 indexed citations
3.
Naranjo, M.E.G., et al.. (2016). High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. The Pharmacogenomics Journal. 16(5). 485–490. 23 indexed citations
4.
LLerena, Adrián, et al.. (2013). Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. The Pharmacogenomics Journal. 14(3). 229–234. 29 indexed citations
5.
López, Marisol, Pedro Dorado, Alberto Ortega, et al.. (2012). Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Molecular Biology Reports. 40(4). 3187–3192. 17 indexed citations
6.
Dorado, Pedro, et al.. (2007). Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5‐HTTLPR‐S) and the CYP2C9*3 allele. Fundamental and Clinical Pharmacology. 21(4). 451–453. 29 indexed citations
7.
8.
LLerena, Adrián, J. Cobaleda, Carmen Martínez, & J. Benítez. (1996). Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. European Journal of Drug Metabolism and Pharmacokinetics. 21(2). 129–138. 70 indexed citations
9.
LLerena, Adrián, Gunnar Edman, J. Cobaleda, et al.. (1993). Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiatrica Scandinavica. 87(1). 23–28. 124 indexed citations
10.
LLerena, Adrián, et al.. (1993). Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clinical Pharmacology & Therapeutics. 54(6). 606–611. 50 indexed citations
11.
Spina, Edoardo, et al.. (1991). Debrisoquine oxidation phenotype during neuroleptic monotherapy. European Journal of Clinical Pharmacology. 41(5). 467–470. 58 indexed citations
12.
Benítez, Julio, Carlos Jara, Juan Antonio Carrillo, et al.. (1991). Polymorphic oxidation of debrisoquine in lung cancer patients. European Journal of Cancer and Clinical Oncology. 27(2). 158–161. 19 indexed citations
13.
Benítez, Julio, José M. Ladero, Adrián LLerena, et al.. (1990). Polymorphic Oxidation of Debrisoquine in Bladder Cancer. Annals of Medicine. 22(3). 157–160. 6 indexed citations
14.
Benítez, J., José M. Ladero, F J Jiménez-Jiménez, et al.. (1990). Oxidative polymorphism of debrisoquine in Parkinson's disease.. Journal of Neurology Neurosurgery & Psychiatry. 53(4). 289–292. 31 indexed citations
15.
Benítez, J., et al.. (1989). Debrisoquine Oxidation Phenotype in Psychiatric Patients. PubMed. 7. 206–210. 6 indexed citations
16.
Ladero, José M., Felipe Jiménez, J. Benítez, et al.. (1989). Acetylator polymorphism in Parkinson's disease. European Journal of Clinical Pharmacology. 37(4). 391–393. 13 indexed citations
17.
Henthorn, Thomas K., Julio Benítez, Michael J. Avram, et al.. (1989). Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clinical Pharmacology & Therapeutics. 45(3). 328–333. 43 indexed citations
18.
Benítez, Julio, Adrián LLerena, & J. Cobaleda. (1988). Debrisoquin oxidation polymorphism in a Spanish population. Clinical Pharmacology & Therapeutics. 44(1). 74–76. 41 indexed citations
19.
Spina, Edoardo, Antoine Buemi, Achille P. Caputi, et al.. (1988). Debrisoquine oxidation in schizophrenic patients treated with neuroleptics. Pharmacological Research Communications. 20(12). 1103–1104. 3 indexed citations
20.
Benítez, J., et al.. (1988). THE DEXTROMETHORPHAN PHENOTYPING TEST ACCURATELY PREDICTS DEBRISOQUIN HYDROXYLASE PHENOTYPE. Anesthesiology. 69(3A). A422–A422. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M L Dahl Breakdown of academic impact, for papers by U. Jeppesen Breakdown of academic impact, for papers by Sachiyo Morita Breakdown of academic impact, for papers by J rgen Brockm ller Breakdown of academic impact, for papers by Jesús Novalbos Breakdown of academic impact, for papers by Karin Kramer Nielsen Breakdown of academic impact, for papers by Linda S. W. Steijns Breakdown of academic impact, for papers by Angela Seeringer Breakdown of academic impact, for papers by Ida Rudberg Breakdown of academic impact, for papers by Arzu Gunes
Rankless by CCL
2026